Abstract：Objective To construct a recombinant lung cancer DNA vaccine with high expression antigen MAGE-A3 in lung cancer and to evaluate its immunogenicity.Methods MAGE-A3 genes were fused with GM-CSF by F2A and cloned into pVAX1 to construct the gene vaccine ppVAX1-MAGE-A3-F2A-GM-CSF. After the gene vaccine was transfected into 293T cells, the expression of the gene vaccine was detected by Western blot and ELISA. Then, the gene vaccine and the control group were injected into the mouse model, and the immune activity was detected by ELISA and ELISPOT.Results Gene vaccine pVAX1-MAGE-A3-F2A-GM-CSF was constructed, and the expression of the antigen was confirmed. After the mice were vaccinated with the gene vaccine, the test Results of ELISA and ELISPOT showed that pVAX1-MAGE-A3-F2A-GM-CSF induced both humoral immune response and cellular immune response compared with the control group.Conclusions pVAX1-MAGE-A3-F2A-GM-CSF can induce both humoral immune response and cellular immune response, and its potential anti-tumor effect needs to be further studied.
Yong X, Xiao Y F, Luo G, et al. Strategies for enhancing vaccine-induced CTL antitumor immune responses[J]. J Biomed Biotechnol, 2012, 2012:605-645.
[7]
Lee S H, Danishmalik S N, Sin J I. DNA vaccines, electroporation and their applications in cancer treatment[J]. Hum Vaccin Immunother, 2015, 11(8):1889-1900.
[8]
Grunwald T, Ulbert S. Improvement of DNA vaccination by adjuvants and sophisticated delivery devices: vaccine-platforms for the battle against infectious diseases[J].Clin ExpVaccine Res, 2015, 4(1):1-10.
[9]
Domingues D, Turner A, Silva M D, et al. Immunotherapy and lung cancer: current developments and novel targeted therapies[J]. Immunotherapy, 2014, 6(11):1221-1235.
[10]
Esfandiary A, Ghafouri-Fard S. MAGE-A3: an immunogenic target used in clinical practice[J]. Immunotherapy, 2015, 7(6):683-704.
2016, Vol. 27 
